MicroPET Outperforms Beta-Microprobes in Determining Neuroreceptor Availability under Pharmacological Restriction for Cold Mass Occupancy by Dorien Glorie et al.
ORIGINAL RESEARCH
published: 10 February 2017
doi: 10.3389/fnins.2017.00047
Frontiers in Neuroscience | www.frontiersin.org 1 February 2017 | Volume 11 | Article 47
Edited by:
Kevin J. Black,
Washington University in St. Louis,
USA
Reviewed by:
Lei Wang,
Northwestern University, USA
Adriaan Anthonius Lammertsma,
VU University Medical Center,
Netherlands
Yi Su,
Washington University in St. Louis,
USA
*Correspondence:
Steven Staelens
steven.staelens@uantwerpen.be
Specialty section:
This article was submitted to
Brain Imaging Methods,
a section of the journal
Frontiers in Neuroscience
Received: 05 October 2016
Accepted: 23 January 2017
Published: 10 February 2017
Citation:
Glorie D, Servaes S, Verhaeghe J,
Wyckhuys T, Wyffels L,
Vanderveken O, Stroobants S and
Staelens S (2017) MicroPET
Outperforms Beta-Microprobes in
Determining Neuroreceptor Availability
under Pharmacological Restriction for
Cold Mass Occupancy.
Front. Neurosci. 11:47.
doi: 10.3389/fnins.2017.00047
MicroPET Outperforms
Beta-Microprobes in Determining
Neuroreceptor Availability under
Pharmacological Restriction for Cold
Mass Occupancy
Dorien Glorie 1, Stijn Servaes 1, Jeroen Verhaeghe 1, Tine Wyckhuys 1, Leonie Wyffels 1, 2,
Olivier Vanderveken 3, Sigrid Stroobants 1, 2 and Steven Staelens 1*
1 Faculty of Medicine and Health Sciences, Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium,
2Nuclear Medicine Department, Antwerp University Hospital, Antwerp, Belgium, 3 Translational Neurosciences, Department
of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine and Health Sciences, University of Antwerp,
Antwerp University Hospital, Antwerp, Belgium
Both non-invasive micro-positron emission tomography (µPET) and in situ
beta-microprobes have the ability to determine radiotracer kinetics and neuroreceptor
availability in vivo. Beta-microprobes were proposed as a cost-effective alternative
to µPET, but literature revealed conflicting results most likely due to methodological
differences and inflicted tissue damage. The current study has three main objectives:
(i) evaluate the theoretical advantages of beta-microprobes; (ii) perform µPET imaging
to assess the impact of (beta-micro)probe implantation on relative tracer delivery (R1)
and receptor occupancy (non-displaceable binding potential, BPND) in the rat brain;
and (iii) investigate whether beta-microprobe recordings produce robust results when
a pharmacological restriction for cold mass dose (tracer dose condition) is imposed.
We performed acquisitions (n = 61) in naive animals, dummy probe implanted animals
(outer diameter: 0.75 and 1.00 mm) and beta-microprobe implanted animals (outer
diameter: 0.75 mm) using two different radiotracers with high affinity for the striatum:
[11C]raclopride (n = 29) and [11C]ABP688 (n = 32). In addition, acquisitions were
completed with or without an imposed restriction for cold mass occupancy. We
estimated BPND and R1 values using the simplified reference tissue method (SRTM).
[11C]raclopride dummy µPET BPND (0.75 mm: −13.01 ± 0.94%; 1.00 mm: −13.89
± 1.20%) and R1 values (0.75 mm: −29.67 ± 4.94%; 1.00 mm: −39.07 ± 3.17%)
significantly decreased at the implant side vs. the contralateral intact side. A similar
comparison for [11C]ABP688 dummy µPET, demonstrated significantly (p < 0.05)
decreased BPND (−19.09 ± 2.45%) and R1 values (−38.12 ± 6.58%) in the striatum
with a 1.00 mm implant, but not with a 0.75 mm implant. Particularly in tracer dose
conditions, despite lower impact of partial volume effects, beta-microprobes proved
unfit to produce representative results due to tissue destruction associated with probe
insertion. We advise to use tracer dose µPET to obtain accurate results concerning
receptor availability and tracer delivery, keeping in mind associated partial volume effects
for which it is possible to correct.
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Glorie et al. Determining Neuroreceptor Availability under Pharmacological Restriction
INTRODUCTION
Brain implants provide valuable information on the central
nervous system. They are commonly used in neuroscience
to deliver drugs by guided cannulas, perform neurochemical
sampling through microdialysis probes, stimulate brain tissue
with deep brain stimulation electrodes, or measure radiotracer
kinetics using beta-microprobes. However, these research tools
are unavoidably invasive as implant diameters frequently exceed
the dimensions of brain tissue components (neurons, capillaries,
and fiber bundles), thereby destroying the integrity of the tissue.
Acute implantation causes changes in the local cerebral blood
flow, metabolism ,and neurotransmitter concentration (Grabb
et al., 1998; Mauger et al., 2005), possibly confounding collected
measurements.
Currently, two preclinical methods are available to determine
radiotracer kinetics and neuroreceptor occupancy in vivo:
in situ beta-microprobes and non-invasive micro-positron
emission tomography (µPET). These techniques provide the
opportunity to measure neuroreceptor changes, associated with
neurodegenerative or psychiatric disease. Following a stereotaxic
implantation in the rat brain, radiosensitive beta-microprobes
can measure the local concentration of a radiolabeled molecule
within a few millimeters around its tip. This technique proved
useful for different purposes; such as cerebral blood flow
measurements (Weber et al., 2003), metabolic studies (Moulin-
Sallanon et al., 2005), radiotracer evaluation (Wyss et al., 2007),
arterial input function measurements (Warnock et al., 2011), and
drug challenge experiments (Ginovart et al., 2004). µPET offers a
non-invasive alternative, by visualizing radiotracer distribution
in the entire brain and enabling longitudinal studies through
intra-animal comparisons. Although, incapable of providing
information on spatial tracer distribution (Märk et al., 2013),
beta-microprobes are suggested as a cost-effective alternative
to µPET. They possess a higher temporal resolution (Zimmer
et al., 2002) to estimate the peak of a time-activity curve,
higher sensitivity (Pain et al., 2008), lower partial volume effect
(Ginovart et al., 2004), and easier coupling with other in vivo
techniques (Desbrée et al., 2004). In addition, beta-microprobes
offer the possibility to perform measurements in awake animals
without restraint combinedwith behavioral observations (Balasse
et al., 2014). To ensure representative results, µPET and beta-
microprobe experiments should comply with low mass tracer
dose (TD) conditions. For TD conditions, the injected mass dose
remains sufficiently low to preserve normal physiology (Hume
et al., 1998; Madsen et al., 2011) with a maximal receptor binding
of 5–10% by the biomarker.
Previously, literature conveyed conflicting results (Zimmer
et al., 2002; Ginovart et al., 2004) on beta-microprobe robustness
and signal-to-noise ratio, probably due to differences in
scintillating tip size (sensitivity), outer diameter (OD) tightly
linked with tissue trauma, injected mass dose, and methodology.
Hence, our aim was to rigorously compare high temporal
resolution yet invasive in situ beta-microprobes vs. whole brain
µPET to evaluate neuroreceptor binding and relative tracer
delivery in vivo. If we assume that beta-microprobes are a viable
alternative to µPET, this might pave the way for a wider use of
beta-microprobes. Beta-microprobes are more easily accessible
compared to µPET, which is associated with relatively high costs
and specialized facilities.
First, we assessed the impact of implantation and probe
OD on tracer delivery and receptor occupancy by inserting
0.75 and 1.00 mm OD dummy probes in the striatum
and cerebellum. Beside, we aimed to clarify whether beta-
microprobes provide a viable alternative to µPET, when TD
is a strict boundary condition. To answer this question, we
performed beta-microprobe acquisitions with the administration
of either a TD or high dose (HD) for a subsequent comparison
to µPET acquisitions. To conduct these experiments, we chose
two different radiotracers with a high affinity for the striatum:
[11C]raclopride ([11C]RAC) for the dopamine D2 receptor
(Alexoff et al., 2003) and [3-(6-methyl-pyridin-2-ylethynyl)-
cyclohex-2-enone-0-11C-methyloxime] ([11C]ABP688) for the
metabotropic glutamate receptor 5 (Ametamey et al., 2007).
The cerebellum, characterized by low specific binding of both
radiotracers, suits as a reference region (Wu and Carson,
2002; Elmenhorst et al., 2010, 2012). After a volume-of-interest
(VOI) analysis of the striatum and cerebellum, we estimated
the non-displaceable binding potential (BPND) in the striatum
and the ratio of tracer delivery to the striatum (tissue of
interest) relative to the delivery in the cerebellum (reference
tissue; R1) using the simplified reference tissue method (SRTM;
Lammertsma and Hume, 1996) for both µPET and beta-
microprobe acquisitions. These physiologically relevant output
parameters provide information on regional receptor availability
(BPND) and perfusion/transport of the radiotracer to the tissue of
interest (R1).
MATERIALS AND METHODS
Study Design
Male Sprague–Dawley rats (n = 61, Harlan Laboratories),
weighing 364 ± 38 g, were treated in accordance with the
European Ethics Committee (decree 86/609/CEE). The study
protocol was approved by the Animal Experimental Ethical
Committee of the University of Antwerp, Antwerp, Belgium.
The animals were kept in individually ventilated cages under
controlled conditions (12 h normal light–dark cycles, 20–23◦C,
and 50–55% relative humidity) with water and rodent food
pellets ad libitum. The study design (Figure 1) was identical for
both radiotracers ([11C]RAC: n = 29 − [11C]ABP688: n = 32).
For each radiotracer the design is subdivided in three separate
experimental groups: a reference µPET group without implants;
a dummy implant µPET group; and a beta-microprobe 0.75 mm
OD implant group. Further subdivisions were made based on
different experimental conditions such as injected dose (TD vs.
HD) and implant diameter. All animals received either a high
dose (target dose of 65MBq; cf.Table 1) or a lowmass tracer dose
being lower than 0.5 nmol/kg (Schiffer et al., 2005) for [11C]RAC
and lower than 3.0 nmol/kg (Wyckhuys et al., 2013) for
[11C]ABP688. Every radiotracer administration was combined
with either a reference µPET-CT scan without implantations
(Figure 1A), a dummy probe implant combined with aµPET-CT
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FIGURE 1 | Study design showing the number of animals in all experimental groups for both [11C]RAC and [11C]ABP688. (A) µPET scans including low
mass tracer dose (TD) and high dose (HD) acquisitions in animals without brain implants as a reference. (B) Assess the impact of the (dummy) implant OD (0.75 vs.
1.00 mm) on radiotracer kinetics and binding using µPET. (C) Clarify whether beta-microprobes provide a viable alternative for µPET, with TD as a boundary
condition. This experiment included TD and HD acquisitions and was carried out using the 0.75 mm OD beta-microprobes. High dose (HD), ±65 MBq; µPET, micro
positron emission tomography; low mass tracer dose (TD), [11C]RAC <0.5 nmol/kg /[11C]ABP688 <3.0 nmol/kg.
TABLE 1 | Average (±s.d.) specific activity (SA) at the time of injection, injected dose (ID), and injected mass (IM) for all experimental groups.
Animals SA (MBq/nmol) ID (MBq) IM (nmol/kg)
n Average ± s.d. Average ± s.d. Average ± s.d.
[11C]RAC
Reference µPET HD 6 93.15 ± 51.86 73.35 ± 1.98 2.86 ± 1.78
Reference µPET TD 5 18.45 ± 4.51 3.31 ± 1.51 0.44 ± 0.11
Dummy µPET TD 0.75 mm 4 57.63 ± 11.65 9.72 ± 2.17 0.48 ± 0.01
Dummy µPET TD 1.00 mm 4 51.26 ± 10.93 9.32 ± 1.23 0.50 ± 0.01
Beta-microprobe HD 0.75 mm 6 65.45 ± 46.07 67.08 ± 8.13 4.77 ± 3.06
Beta-microprobe TD 0.75 mm 4 38.49 ± 10.98 7.24 ± 0.50 0.52 ± 0.03
[11C]ABP688
Reference µPET HD 6 48.77 ± 15.97 69.81 ± 3.45 4.48 ± 2.01
Reference µPET TD 6 17.34 ± 3.66 20.81 ± 5.63 2.90 ± 0.32
Dummy µPET TD 0.75 mm 4 18.53 ± 2.26 16.82 ± 1.12 2.72 ± 0.09
Dummy µPET TD 1.00 mm 4 17.97 ± 2.70 16.40 ± 0.50 2.73 ± 0.07
Beta-microprobe HD 0.75 mm 6 47.18 ± 24.55 65.68 ± 3.33 5.60 ± 3.93
Beta-microprobe TD 0.75 mm 6 16.81 ± 1.10 15.32 ± 2.34 2.52 ± 0.33
HD, high dose; ±65 MBq; ID, injected dose; IM, injected mass; PET, positron emission tomography; SA, specific activity; s.d., standard deviation; low mass tracer dose (TD), [11C]RAC
<0.5 nmol/kg /[11C]ABP688 <3.0 nmol
scan (Figure 1B), or a beta-microprobe implant and acquisition
(Figure 1C). The dummy µPET experimental group was further
subdivided in separate implant groups depending on the
OD and thus the inflicted tissue trauma (Figure 3). These
dummy groups were mandatory since simultaneous µPET and
beta-microprobe acquisitions are practically unfeasible as the
actual scintillation probes are non-disposable and cannot be
permanently fixed with dental cement (cf. Section Experimental
Procedure). Three out of 64 subjects (n = 61) were left out
for further analysis due to surgical complications (bleeding) or
when the maximal allowed cold mass was exceeded for TD
conditions.
Experimental Procedure
For the reference µPET-CT scans (Figure 1A), the
animals were anesthetized (2% isoflurane mixed with
medical oxygen). After the insertion of a catheter in
the tail vein for tracer administration, the animals were
positioned on the heated bed (37.5◦C) of the µPET-CT
scanner.
For beta- and dummy probe implantations (Figures 1B,C),
the animal was anesthetized (2% isoflurane mixed with medical
oxygen) ∼90 min before radiotracer administration and placed
on a heated blanket (37.5◦C). Before surgery, a catheter was
placed in the tail vein for tracer administration. Subsequently,
the head of the animal was fixated in a stereotaxic frame (Kopf
Instruments, California, USA). After making an anteroposterior
incision toward the neck region, the skull was exposed by
retraction of the skin and muscle layers. Two holes were
drilled in the skull for probe positioning, one at the level of
the right striatum and another at the level of the cerebellum.
The anteroposterior (AP) and mediolateral (ML) stereotaxic
coordinates were determined relative to the bregma. The surface
of the dura functioned as a reference point for the dorsoventral
(DV) coordinate. Implant coordinates were obtained from a
rat brain atlas (Paxinos and Watson, 2013): AP +0.2, ML
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3.0, DV −6.0 for the striatum and AP −11.8, ML 0.0, and
DV −3.5 for the cerebellum. Finally, the dummy probes
(0.75 mm or 1.00 mm OD) or beta-microprobes (0.75 mm
OD) were positioned. Beta-microprobe animals remained on
the heated blanket and were coupled to the light-tight Beta
Scintillator System Twin (Swisstrace, Zurich, Switzerland; Weber
et al., 2003; Wyss et al., 2007), awaiting immediate tracer
administration. Dummy probe animals were transferred to
the µPET-CT scanner (Siemens Preclinical Solution, Knoxville,
TN, USA) after fixation of the dummy probes on the
skull with dental cement (prorep propal, Belgica Dental,
Belgium).
Concerning the synthesis of both radiotracers, [11C]RAC
was synthesized by O-methylation of (S)-O-desmethylraclopride
precursor (ABX, Raderberg, Germany) with 11C-CH3O3SCH3.
11C-CO2 was produced in an Eclips HP cyclotron (Siemens,
Knoxville, TN, USA) by irradiation of a N2 target for 50 min with
an 11 MeV proton beam and a beam intensity of 60 µA. The
11C-CO2 was converted to
11C-CH3O3SCH3 for reaction with
(S)-O-desmethylraclopride via 11C-CH3I. The radiochemical
purity was determined by reverse phase high-performance liquid
chromatography (HPLC) (Waters Symmetry C18, 3.5 µm, 4.6 ×
50 mm) and was ≥99.9%. The purified [11C]RAC was dissolved
in a mixture of NaH2PO4 0.005M pH 4.5, 0.9% NaCl (B. Braun,
Germany) and ethanol 96% v/v (BP, Eur.Ph., Merck-Chemicals,
Darmstadt, Germany). The solution was sterile filtered for in vivo
use. [11C]ABP688-E is prepared by reaction of 0.5mg desmethyl-
ABP688 (E/Z) with 11C-CH3SO3CF3 in 400 µL acetone in the
presence of 10 µL 1N NaOH for 4 min at room temperature.
For purification, the crude reaction mixture was injected into
an analytical HPLC column (WatersXBridge C18, 5 µm, 4.6 ×
150 mm) with an eluent of 0.05 M sodium acetate (pH 5.5)
and ethanol (55/45, v/v) at a flow rate of 1 mL/min to isolate
the [11C]ABP688-E. The purified [11C]ABP688-E is filtrated
through a sterileMilliporeMillex-GV filter (0.22µm) and diluted
with 0.9% NaCl through the same filter to reduce the ethanol
concentration to <10%. The average specific activity, injected
dose, and injected mass dose for all experimental groups are
shown in Table 1. In order to keep the injected mass dose below
the imposed limit of 0.5 nmol/kg for [11C]RAC and 3.0 nmol/kg
for [11C]ABP688, injected doses in the TD groups accurately
compensate for the varying specific activity of each radiotracer
production.
Data Acquisition
The reference µPET and the dummy implant groups received
a dynamic µPET-CT scan (Figures 1A,B) performed on
two Siemens Inveon µPET-CT scanners (Siemens Preclinical
Solution, Knoxville, TN, USA) with the following specifications:
60-min dynamicµPET acquisitions with 2× 10 s, 3× 20 s, 3× 30
s, 3× 60 s, 3× 150 s, 9× 300 s frames, followed by a 7-min µCT.
Scans were started immediately after positioning the animal on
the scanner and administration of a bolus of radiotracer via
the tail vein. All animals were randomly distributed on both
scanners.
For beta-microprobe recordings (Figure 1C), the light-tight
Beta Scintillator System Twin was switched on at least 30 min
before recording to ensure a sufficient warm-up and stabilization
of the photomultiplier tubes (Ginovart et al., 2004). The system
was equipped with 0.75 mm OD scintillator probes. After
implantation, recordings at a sampling rate of 1 Hz were started 1
min before tracer administration for count stabilization followed
by a 60-min acquisition using PMOD v3.0 (PMOD technologies,
Zurich, Switzerland). Finally, the animals were removed from
the stereotaxic frame and the scintillator probes were cleansed
with water. All animals were injected with an overdose of
pentobarbital (>30 mg/kg) at the end of each acquisition (beta-
microprobe and dummy µPET). Upon immediate removal,
their brain was submerged in cooled 2-methylbutane and
stored at −20◦C for a subsequent histological verification
of the probe position in coronal cryosections (20 µm).
Cryosections confirmed correct dummy probe localization for all
subjects.
Both µPET scanners were calibrated using a uniform cylinder
with known activity (±37 MBq; room temperature) to obtain a
calibration factor for conversion of images to kBq/cc. Calibration
(sampling rate: 1 Hz; duration: 60 s) of beta-microprobes was
achieved by immersion in an aqueous solution (10 mL) with
a known activity concentration of [11C]ABP688 (±20 MBq;
room temperature). Probes were repetitively calibrated (similar
experimental conditions) in order to determine an averaged
calibration factor for each probe.
Data Analysis
For quantitative image analysis,µPET images were reconstructed
using two-dimensional ordered subset expectation maximization
with four iterations and 16 subsets after Fourier rebinning. The
images were reconstructed on a 128 × 128 × 159 grid with
a voxel size of 0.776 × 0.776 × 0.796 mm. Normalization,
dead time correction, random subtraction, CT-based attenuation
correction, and single-scatter simulation scatter corrections were
applied. For both tracers, reconstructed images were processed in
PMOD v3.3. A static image corresponding to the time-averaged
frames of each dynamic acquisition was spatially transformed
through brain normalization to a rat brain template for [11C]RAC
and [11C]ABP688 (in-house developed; Verhaeghe et al., 2014).
Both PET templates already corresponded to a standardized
MR template space (Schiffer rat MR; available in PMOD v3.3)
with corresponding VOI definition. The obtained matrix from
the brain normalization step was applied to transform all
dynamic scans to the [11C]RAC and [11C]ABP688 template
space, respectively. The time-activity curves of the striatum and
cerebellar VOI were extracted from the resulting images via the
superimposition of a VOI template. The extracted time-activity
curves served as input for the SRTM (Lammertsma and Hume,
1996). This kinetic modeling method allows quantification of
receptor kinetics in a region of interest via the expression
of tracer uptake in this tissue in terms of its uptake in a
reference region (devoid of the receptor-of-interest) with a
similar level of non-specific binding. Based on this method
(which is implemented in PMOD software), the BPND and
relative delivery R1 of the tracer to the striatal VOI were
calculated, with the cerebellum as a reference region. In addition,
pixel wise kinetic modeling, using SRTM2 (Wu and Carson,
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2002), was applied to generate parametric BPND and R1
maps.
For each beta-microprobe experiment, the recorded time-
activity curves of the striatum and cerebellum were decay
corrected for 11C with respect to the timing of radiotracer
injection (PMOD v3.5). The individual probe sensitivity,
represented by a mean calibration factor for each probe, was
applied to convert measured counts per second (cps) into
radioactive concentration (kBq/cc) (PMOD v3.5). The resulting
time-activity curves were resampled to µPET frame duration (2
× 10 s, 3 × 20 s, 3 × 30 s, 3 × 60 s, 3 × 150 s, 9 × 300 s) to
reduce the increasing statistical counting noise, arising from the
rapid decay of 11C. The corrected time-activity curve data points
for both probes (striatum and cerebellum) were fitted using the
SRTM to obtain the BPND and R1 parameters for individual
measurements.
Data are expressed as the averaged BPND and R1 ± standard
error of the mean (s.e.m.) for each experimental group. The
statistical significance of these SRTM output values (striatum)
for both µPET and beta-microprobe experiments was evaluated
using a non-parametric Mann–Whitney test in GraphPad Prism
6 (GraphPad Software, San Diego, USA). Differences were
considered statistically significant at p < 0.05.
RESULTS
Radiotracer Dosing Impacts the Degree of
Receptor Occupancy Reflected by the
Non-displaceable Binding Potential (BPND)
Parameter
When comparing two dose conditions (TD and HD) using
reference (without implant) µPET scans, the HD, and TD
cerebellar time-activity curves both show the characteristic
temporal profile of a reference region with a fast decline toward
a low level (±0.1%ID/cc) for both radiotracers (Figure 2).
FIGURE 2 | Averaged injected dose corrected time-activity curves (±s.e.m.) with the corresponding BPND and R1 values for [
11C]RAC and
[11C]ABP688 reference HD and TD µPET experiments. The left panels show the averaged injected dose corrected time-activity curves for HD (±65 MBq) vs. TD
([11C]RAC: <0.5 nmol/kg; [11C]ABP688: <3.0 nmol/kg) µPET experiments, for [11C]RAC (A) and [11C]ABP688 (B), respectively. The average BPND and R1 values
(±s.e.m.) are displayed with the corresponding box-plot (right panels). The asterisks indicate significant (p < 0.05) differences in BPND or R1 values after a
non-parametric Mann–Whitney test. CB, cerebellum; HD, high dose ±65 MBq; ID/cc, injected dose/cubic centimeter; PET, positron emission tomography; STR,
striatum; TD, low mass tracer dose [11C]RAC <0.5 nmol/kg /[11C]ABP688 <3.0 nmol/kg.
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Evidently, the corresponding striatal time-activity curves differ
in temporal profile: the HD striatal time-activity curves visibly
decline to a lower level for both tracers compared to the TD
time-activity curves. This “dose effect” is more pronounced for
the [11C]RAC striatal time-activity curves (Figure 2A) reflected
by the corresponding BPND values (Figures 2A,B box-plots):
a HD (±65 MBq) administration of [11C]ABP688 caused
a 8.94% (±0.33%) decrease in the striatal BPND compared
with TD (<3.0 nmol/kg) µPET experiments (Figure 2B). A
similar HD BPND decrease is more pronounced for [
11C]RAC
(−30.48 ± 2.04%), which reached significance (p = 0.0173;
Figure 2A).
Histology Confirms a Disproportional
Impact of Probe Outer Diameter on Tissue
Damage
High-resolution µCT images (Figures 3A,B) confirm similar
scintillating tip dimensions (1.00 mm length–0.50 mm diameter)
in both beta-microprobe sets, which results in a similar
sensitivity with however a difference in outer diameter (0.75
and 1.00 mm) by additional coating. Cryosections show
tissue damage with both beta-microprobe sets (Figures 3C,D)
disproportionally increasing with outer diameter. Additionally,
our in-house dummy probes for µPET imaging were
designed to have a similar shape and size (Figures 3E,F)
and proved suitable to mimic the inflicted damage from
beta-microprobe implantations, for both the 0.75 mm
(Figure 3C) and 1.00 mm (Figure 3D) OD beta-microprobe
set.
Probe Implantation Affects Both
Radiotracer Perfusion and Receptor
Occupancy
Figure 4A ([11C]RAC) and Figure 5A ([11C]ABP688) illustrate
the corresponding time-activity curves for the cerebellum and
the striatum of the reference µPET as well as the TD µPET
experiments for both the 0.75 and 1.00 mm OD dummies
compared to the intact hemisphere. The striatal time-activity
curves of dummy implanted rats differed in temporal profile
compared to reference µPET striatal time-activity curves and
compared to the intact contralateral side, especially at the level of
the peak and significantly more pronounced for 1.00mm dummy
probes.
In both [11C]RAC dummy groups, when comparing the
implant (white arrows) and intact striatal VOIs, the BPND
maps (Figure 4B) and R1 maps (Figure 4C) show significant
(p < 0.05) decreases in BPND (0.75 mm: −13.01 ± 0.94%;
1.00 mm: −13.89 ± 1.20%) and R1 values (0.75 mm: −29.67
± 4.94%; 1.00 mm: −39.07 ± 3.17%) at the implant side
(Figures 4D,E). Also, the averaged R1 values demonstrated
significant (p < 0.05) reductions at the implant side for both
dummy groups relative to the averaged reference µPET R1 value
(Figure 4E).
For [11C]ABP688, a comparison between both sides
(Figures 5B,C) revealed significantly (p < 0.05) decreased
BPND (−19.09 ± 2.45%) and R1 values (−38.12 ±
6.58%) at the implant side of the 1.00 mm dummy group
(Figures 5D,E). Also, the R1 values of the striatal VOIs with
implant (Figure 5E) significantly differed (0.75 mm: p <
0.05 and 1.00 mm: p < 0.01) from the averaged reference
TD µPET R1 value (0.82 ± 0.03). For [11C]ABP688,
the BPND seems to be less influenced by the 0.75 mm
implants.
Tracer Dose Beta-Microprobe
Acquisitions: Not a Viable Alternative to
Tracer Dose µPET
Based on the results of the previous section, the 0.75 mm
OD beta-microprobe set was selected for beta-microprobe
recordings. The averaged and injected dose corrected
FIGURE 3 | Illustration of the internal composition of the available beta-microprobe sets and inflicted implant damage to the rat brain. (A,B) High
resolution µCT-images from (A) 0.75 mm OD and (B) 1.00 mm OD beta-microprobes. (C–F) Results from the histological verification of probe localization in coronal
cryosections of the striatum (indicated by STR; brain outline adapted from Paxinos and Watson) (Paxinos and Watson, 2013). The gray insets show the corresponding
implanted probe for each cryosection: (C) 0.75 mm beta-microprobe; (D) 1.00 mm beta-microprobe; (E) 0.75 mm dummy probe; (F) 1.00 mm dummy probe.
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FIGURE 4 | [11C]RAC average injected dose corrected time-activity curves (±s.e.m.) combined with the corresponding BPND and R1 maps/values
from TD reference and dummy µPET experiments. (A) [11C]RAC reference and dummy (0.75 and 1.00 mm) µPET time-activity curves (±s.e.m.) for the
cerebellum (reference region) and the striatum (region of interest). Dummy groups received a probe implantation in both the cerebellum and striatum in contrast to the
reference group. (B,C) Average transversal BPND (B) and R1 (C) maps for the reference, 0.75 mm OD dummy, and 1.00 mm OD dummy µPET groups overlaid on a
magnetic resonance (MR) template. The white arrows point out the side of dummy implantation. (D,E) Box-plot representation of the BPND (D) and R1 (E) values
obtained from TD µPET experiments (with and without dummy implants). The average BPND and R1 values (±s.e.m.) are displayed at the bottom of the
corresponding graph. The asterisks indicate significant (p < 0.05) differences in BPND or R1 values using a non-parametric Mann–Whitney test. Remark: the
time-activity curves from [11C]RAC reference TD µPET acquisitions (Figure 2A) were repeated here for a sufficient comparison of data. BPND, non-displaceable
binding potential; ID/cc, injected dose/cubic centimeter; PET, positron emission tomography; R1, relative delivery; TD, low mass tracer dose <0.5 nmol/kg.
time-activity curves for HD and TD beta-microprobe
acquisitions are illustrated in Figure 6 for both [11C]RAC
and [11C]ABP688. The corresponding averaged BPND and R1
values are shown in Table 2.
For TD recordings, the tail of the cerebellar reference
curve distends (±3000 s) upon decay correction. A
subsequent application of the SRTM to TD data resulted
in inaccurate outcome parameters, producing a lower
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FIGURE 5 | [11C]ABP688 average injected dose corrected time-activity curves (±s.e.m.) combined with the corresponding BPND and R1 maps/values
from TD reference and dummy µPET experiments. (A) [11C]ABP688 reference and dummy (0.75 and 1.00 mm) µPET time-activity curves (±s.e.m.) for the
cerebellum (reference region) and the striatum (region of interest). Dummy groups received a probe implantation in both the cerebellum and striatum in contrast to the
reference group. (B,C) Average transversal BPND (B) and R1 (C) maps for the reference, 0.75 mm OD dummy, and 1.00 mm OD dummy µPET groups overlaid on a
magnetic resonance (MR) template. The white arrows point out the side of dummy implantation. (D,E) Box-plot representation of the BPND (D) and R1 (E) values
obtained from TD µPET experiments (with and without dummy implants). The average BPND and R1 values (±s.e.m.) are displayed at the bottom of the corresponding
graph. The asterisks indicate significant (*p < 0.05/**p < 0.01) differences in BPND or R1 values using a non-parametric Mann–Whitney test. Remark: the time-activity
curves from [11C]ABP688 reference TD µPET acquisitions (Figure 2B) were repeated here for a sufficient comparison of data. BPND, non-displaceable binding
potential; ID/cc, injected dose/cubic centimeter; PET, positron emission tomography; R1, relative delivery; TD, low mass tracer dose <3.0 nmol/kg.
BPND value (Table 2) compared with HD recordings
and conflicting with the reference µPET experiment
(Figure 2).
HD recordings, where TD conditions are exceeded, yield
lower average BPND values (Table 2) compared to reference TD
µPET (Figure 2).
DISCUSSION
In the present study, we (i) evaluated theoretical advantages
associated with beta-microprobe recordings, (ii) assessed the
impact of implantation and probe OD on relative tracer delivery
and receptor occupancy using reference and dummyµPET scans,
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FIGURE 6 | Average injected dose corrected time-activity curves (±s.e.m.) measured by a beta-microprobe in a high-binding region (striatum) and
reference region (cerebellum) after [11C]RAC or [11C]ABP688 administration. (A) [11C]RAC striatal (without markers) and cerebellar (with markers)
time-activity curves from 0.75 mm OD beta-microprobe measurements using varying dose conditions (TD vs. HD). (B) [11C]ABP688 striatal (without markers) and
cerebellar (with markers) time-activity curves from 0.75 mm OD beta-microprobe measurements using varying dose conditions (TD vs. HD). CB, cerebellum; HD, high
dose ±65 MBq; ID/cc, injected dose/cubic centimeter; STR, striatum; TD, low mass tracer dose [11C]RAC<0.5 nmol/kg /[11C]ABP688<3.0 nmol/kg.
TABLE 2 | [11C]RAC and [11C]ABP688 average (±s.e.m.) striatal BPND and
R1 values from HD and TD dose beta-microprobe measurements using a
0.75 mm OD beta-microprobe set.
Animals BPND striatum R1 striatum
n Average ± s.e.m. Average ± s.e.m.
[11C]RAC BETA-MICROPROBE
HD 0.75 mm 6 2.12 ± 0.23 0.80 ± 0.08
TD 0.75 mm 4 1.65 ± 0.12 0.65 ± 0.08
[11C]ABP688 BETA-MICROPROBE
HD 0.75 mm 6 2.12 ± 0.25 0.93 ± 0.13
TD 0.75 mm 6 1.31 ± 0.10 0.72 ± 0.06
BPND, non-displaceable binding potential; HD, high dose ±65 MBq; R1, relative delivery;
s.e.m., standard error of the mean; TD, low mass tracer dose [11C]RAC<0.5 nmol/kg/
[11C]ABP688 <3.0 nmol/kg.
and (iii) addressed whether recordings with beta-microprobes
produce representative results when TD is imposed as boundary
condition. Beta-microprobe recordings proved unfit to produce
representative results, primarily due to the destructive effect
of inserting a probe in brain tissue, especially in the context
of low counts associated with the administration of a low
mass TD.
The reference striatal BPND values from our TD µPET
experiments in intact animals agree very well with literature
for both [11C]RAC (Hoekzema et al., 2010; Topping et al.,
2010) and [11C]ABP688 (Elmenhorst et al., 2012). The collection
of accurate ligand-receptor binding data—avoiding BPND
underestimation—requires the amount of cold ligand to remain
below an imposed limit, insuring 5–10% receptor occupancy
(TD conditions; Hume et al., 1998; Kung and Kung, 2005).
The application of such a limit alludes to eliminate a possible
disruption of normal physiology. In general, a higher amount
of cold stable ligand lowers the opportunity for the hot ligand
to bind its target. For [11C]RAC, an additional drug effect
from the radiotracer itself on presynaptic dopamine receptors
could induce extra endogenous dopamine release, contributing
to such underestimation (Morris et al., 2014). For [11C]ABP688,
the effect of endogenous glutamate levels on [11C]ABP688
binding in the rat brain remains controversial (Wyckhuys
et al., 2013; Zimmer et al., 2015). Our data (Figure 2) show a
correlation between the extent of BPND underestimation and
exceeding the TD limit (based on the affinity of the tracer
for its target) as the application of the same HD (±65 MBq)
violates TD conditions with a factor 6.50 for [11C]RAC (<0.5
nmol/kg) and with a factor 1.54 for [11C]ABP688 (<3.0 nmol/kg;
Table 1). Consequently, HD administration produces a more
pronounced effect on [11C]RAC time-activity curves reflected
by a larger BPND underestimation, as clearly illustrated by
Figure 2.
A major theoretical advantage of beta-microprobes includes
their high temporal resolution to capture the peak of the
time-activity curve. However, during time-activity curve pre-
processing and in accordance with literature (Pain et al., 2002;
Zimmer et al., 2002; Ginovart et al., 2004; Moulin-Sallanon et al.,
2005; Märk et al., 2013; Balasse et al., 2014), we were forced to
resample the curves to larger time frames due to high signal noise
associated with beta-microprobe recordings. We resampled the
data to µPET frames: 2 × 10 s, 3 × 20 s, 3 × 30 s, 3 × 60 s, 3 ×
150 s, 9 × 300 s. In this way, the beneficial theoretical temporal
resolution of 1 s was lost.
Although, both systems were calibrated accurately, the
[11C]RACHD striatal time-activity curve of the beta-microprobe
recording is of similar shape but proportionally higher compared
to the HD striatal time-activity curve of µPET acquisitions over
its entire course. This results in a higher BPND value. More
specifically, the HD beta-microprobe striatal time-activity curve
peaks at±1.3% ID/cc and decreases to±0.5% ID/cc (Figure 6A)
at the end of the acquisition, while the HD µPET striatal curve
peaks at ±1.0% ID/cc and ends at ±0.2% ID/cc (Figure 2A).
This comparison between the [11C]RAC HD striatal time-
activity curves of both methods points out an underestimation
of [11C]RAC binding by µPET, caused by spill-out of the
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striatal VOI (partial volume effect). This phenomenon could
not be deduced from [11C]ABP688 HD striatal time-activity
curves for both methods. We suggest the tracer-specific
distribution pattern as a possible cause. [11C]ABP688 binding
is characterized by spill-in from surrounding brain regions in
the striatal volume of interest, causing an artificial increase in
the HD µPET striatal curve (Figure 2B). Thereby, balancing
the existing striatal spill-out of the tracer. This contrasts with
[11C]RAC, which only binds striatal dopamine D2 receptors
and consequently is not subjected to spill-in signal from
surrounding tissues (devoid of D2 receptors). Indeed, as visible
on the obtained BPND maps and as anticipated, [
11C]RAC
binding (Figure 4B) was restricted to the striatum, whereas
[11C]ABP688 (Figure 5B) also binds regions surrounding the
striatum.
The impact of probe implantation on measurements is
detrimental for beta-microprobe data. µPET TD acquisitions
with dummy probes in both the striatum and cerebellum
confirmed a disruptive effect on local striatal receptor binding
(BPND) and -to a larger extent- on relative tracer delivery to
the implant region (R1). This differs from previous findings
showing that insertion of a microdialysis probe (0.34 mm OD)
in the striatum does not significantly influences local [11C]RAC
receptor binding (Schiffer et al., 2005, 2006). We suggest two
possible explanations for this finding: (i) This may be attributable
to the relatively large OD of the inserted probe (0.75 mm) in
beta-microprobe studies, which is in line with the established
relation between increasing OD and relative tracer delivery. (ii)
In contrast to the aforementioned studies where µPET images
were acquired 2 days post implantation, we assessed implant
effects immediately upon insertion (mimicking a typical beta-
microprobe acquisition) thereby excluding possible adaptation
mechanisms. In addition, one previous study revealed a 60%
decrease in blood flow to the implant region after insertion
of a 0.30 mm OD implant (Benveniste et al., 1987). Due to
the dynamic relation between cerebral blood flow and drug
delivery to the brain, we suggest a similar influence on tracer
delivery to the damaged implant area, reflected by a visible
decrease in the R1 parameter at the implant side. Subsequently,
such decrease in R1 is inextricably linked to a decrease
in BPND.
Another phenomenon which possibly contributes to
erroneous SRTM estimates for implanted animals is the
possible presence of blood-brain barrier damage. The SRTM
assumes an equal K1/k2 and K1′/k2′ for both the target and
reference region(s). This implies an intact blood-brain barrier
for both regions. Based on possible differences in the extent
of blood-brain barrier damage between both regions, this
assumption could become invalid thereby affecting the validity of
SRTM. Additionally, we found erroneous SRTM estimates (BPND
and R1) for beta-microprobe TD recordings due to a distorted
cerebellar time-activity curve. During pre-processing, the applied
11C decay correction on this reference curve caused the tail to
distend. This effect is more pronounced for [11C]RAC compared
to [11C]ABP688 recordings, likely caused by the reliability of
the reference region as the cerebellum is completely devoid
of dopamine D2 receptors, but yet contains a small amount
of metabotropic glutamate receptor 5. However, also for TD
[11C]ABP688 beta-microprobe data our group (Wyckhuys et al.,
2013) previously showed that beta-microprobes underestimated
the striatal BPND. The aforementioned problem with the
cerebellar reference curve did not occur in previously published
beta-microprobe studies with [11C]RAC using the SRTM,
because all these studies substantially exceeded the upper limit
for cold mass of 0.5 nmol/kg or so-called TD condition (Zimmer
et al., 2002; Ginovart et al., 2004; Balasse et al., 2014). And indeed,
the time-activity curves of our HD [11C]RAC beta-microprobe
recordings, are consistent with such high activity curves (Balasse
et al., 2014), peaking and declining to similar levels of %ID/cc.
Therefore, we conclude that -to the best of our knowledge-
the vast majority of beta-microprobe literature involves the
application of a HD, thereby perturbing physiology causing
underestimation of the BPND.
In contrast to a theoretically expected higher BPND value
for TD beta-microprobe measurements compared to TD µPET
acquisitions, we found the opposite. We suggest that, although
beta-microprobes suffer less from partial volume effects, the
implant effect drastically distorts acquired results, especially in
low signal-to-noise measurements with cold mass restriction.
This was confirmed by the beta-microprobe data where the
implant effect showed less pronounced upon injection of a HD,
most likely due to the presence of sufficient counts, despite the
damage. However, to obtain representative results (especially
in rodents) TD conditions should always be applied, which in
our hands resulted in erroneous SRTM estimates when using
beta-microprobes. Also, the use of a beta-microprobe with a
smaller OD and consequently lower associated damage would not
provide a solution due to the trade-off between tip dimensions
and sensitivity.
In conclusion, beta-microprobes are not preferred due to the
decisive and disruptive effect of probe insertion on delivery and
binding of a radiotracer to a target tissue. Keeping in mind the
occurrence of partial volume effects and the absence of a golden
standard, we suggest to use TD µPET to produce reliable results.
This approach offers the additional opportunity to perform
longitudinal study designs, thereby repetitively acquiring whole
brain information without the need to sacrifice the animal.
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